Data as of May 24
| +0.01 / +0.01%|
The 9 analysts offering 12-month price forecasts for Pharmacyclics Inc have a median target of 97.00, with a high estimate of 165.00 and a low estimate of 70.00. The median estimate represents a +13.30% increase from the last price of 85.61.
The current consensus among 14 polled investment analysts is to Buy stock in Pharmacyclics Inc. This rating has held steady since May, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.